AbbVie (ABBV) EPS (Basic) (QoQ) (2012 - 2026)
Powered by 
Analysis
AbbVie (ABBV) EPS (Basic) (QoQ) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.46 Bn | 621.70 Bn | 17.26 Bn |
| 2 | AbbVie | 447.01 Bn | 440.44 Bn | 12.70 Bn |
| 3 | Merck | 358.21 Bn | 351.07 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.54 Bn | 259.85 Bn | 11.24 Bn |
| 5 | Pfizer | 156.67 Bn | 144.97 Bn | 10.94 Bn |
| 6 | Sanofi | 52.23 Bn | 44.85 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.86 Bn | 42.86 Bn | - |
| 8 | Incyte | 24.60 Bn | 20.06 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.31 Bn | 18.64 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.83 Bn | 15.44 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 419.09% |
| Mar 31, 2026 | -61.62% |
| Dec 31, 2025 | 865.43% |
| Sep 30, 2025 | -80.03% |
| Jun 30, 2025 | -27.00% |
| Mar 31, 2025 | 5,707.52% |
| Dec 31, 2024 | -101.47% |
| Sep 30, 2024 | 13.85% |
| Jun 30, 2024 | 0.13% |
| Mar 31, 2024 | 66.41% |
| Dec 31, 2023 | -53.76% |
| Sep 30, 2023 | -12.14% |
| Jun 30, 2023 | 2,193.24% |
| Mar 31, 2023 | -103.93% |
| Dec 31, 2022 | -37.45% |
| Sep 30, 2022 | 325.62% |
| Jun 30, 2022 | -79.33% |
| Mar 31, 2022 | 11.01% |
| Dec 31, 2021 | 27.20% |
| Sep 30, 2021 | 313.29% |